A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
You may be eligible for this study if you meet the following criteria:
- Conditions: anal cancer
Age: Between 18 Years - 100 Years
Gender: Male or Female
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Patients must have histologically proven stage II (T3N0 only), IIIA, or IIIB invasive anal (anal margin) squamous cell carcinoma; this may include tumors of non-keratinizing histology such as basaloid, transitional cell, or cloacogenic histology
- Patients will be excluded if they have a T1, T2N0 or M1 cancer
For a full list of participation criteria, please visit clinicaltrials.gov.Additional Information:
Connect with a study center near you
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting